Dishman Pharmaceuticals and Chemicals has successfully crossed Rs 1000 crore milestone in respect of consolidated net sales during 2008-09 and achieved a growth of 32.3 per cent. Its consolidated net sales reached at Rs 1062 crore as against Rs 803.08 crore in the previous year. Its consolidated net profit increased by 22.1 per cent to Rs 146.19 crore from Rs 119.71 crore. With better growth in bottom line, its earning per improved to Rs 18.13 as against Rs 15.70 in the last year.
The board of directors has recommended the equity dividend at the rate of 60 per cent (Rs 1.20 per share of Rs 2 each) for the year 2008-09.
Dishman's revenues from CRAMS jumped by 29.2 per cent to Rs 777.38 crore from Rs 601.62 crore and that from marketable molecules increased sharply by 56.1 per cent to Rs 284.98 crore from Rs 182.61 crore. The company's operating profit before interest, depreciation and taxation has taken quantum jump of 63.6 per cent to Rs 266.22 crore from Rs 162.68 crore. Its interest charges increased sharply by more than 50 per cent to Rs 45.85 crore from Rs 30.50 crore.
The company's standalone net sales for the year 2008-09 reached at Rs 415.88 crore from Rs 359.20 crore, a growth of 15.8 per cent and it earned a net profit of Rs 92.15 crore as compared to Rs 59.56 crore, a jump of 54.7 per cent.